Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC59H71N7O15 |
InChIKeyZIINLNWQOBVXNW-MMWJDCCRSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 21 Feb 2020 | |
Neoplasms | Preclinical | DE | 21 Feb 2020 |